UBC PiMS Research Group
Pharmacoepidemiology in Multiple Sclerosis Research Group

Hilda de Jong

Hilda_profile_2012Academic Status: Postdoctoral Fellow

Previous Academic Training: PhD in Pharmacoepidemiology (Maastricht University Medical Center, The Netherlands), MSc and BSc in Human Nutrition and Epidemiology (Wageningen University, The Netherlands)

UBC Academic Department: Department of Medicine, Division of Neurology

Supervisor(s): Dr. Helen Tremlett, PhD

Project title(s): The BeAMS study: The long-term Benefits and Adverse effects of Beta-interferon for Multiple Sclerosis

New indications for old drugs: Do statins, angiotensin converting enzyme inhibitors (ACEIs) or proton pump inhibitors (PPIs) impact long-term disease progression in MS?

Email: hdejong@mail.ubc.ca

Awards Received:

  • MS Society of Canada Postdoctoral Fellowship (2013-2016)
  • Michael Smith Foundation for Health Research Trainee Postdoctoral Fellowship (2013-2016)
  • MS Society of Canada endMS Scholar Program for Researchers IN Training (SPRINT) Trainee (2014-2015)
  • International Conference on Pharmacoepidemiology & Therapeutic Risk Management Student Travel Scholarship (2011, 2013)
  • MS Society of Canada endMS Summer School Travel and Training Award (2012, 2013)
  • United European Gastroenterology Week Basic Scientist Travel Award (2012)
  • Dutch Society for Immunology Student Travel Award (2011)
  • International Conference on Pharmacoepidemiology & Therapeutic Risk Management Student Travel Scholarship (2011)
  • Dutch Arthritis Association Student Travel Award (2011)

 

Publications:

  • de Jong HJ, Meyboom RH, Klungel OH, Niskanen L, Cohen Tervaert JW. Giant cell arteritis/ polymyalgia rheumatica after re-exposure with a statin. Ann Intern Med. 2014; 161(8):614-5
  • de Jong HJ, Korevaar JC, Van Dijk L, Voogd E, Van Dijk CE, Van Oijen MG. Suboptimal prescribing of proton pump inhibitors in low-dose aspirin users in general practice: a population based cohort study. BMJ Open. 2013; 3(7): doi:pii: e003044.
  • Vandebriel RJ, de Jong HJ, Gremmer ER, Klungel OH, Tervaert JW, Slob W, Van Der Laan JW, Van Loveren H. Response to ‘Statins accelerate the onset of collagen type II-induced arthritis in mice’-authors’ reply. Arthritis Res Ther. 2013; 15(2): 403
  • de Jong HJ, Damoiseaux JG, Vandebriel RJ, Souverein PC, Gremmer E, Wolfs M, Klungel OH, Van Loveren H, Cohen Tervaert JW, Verschuren WM. Statin use and markers of immunity in the Doetinchem Cohort Study. PLoS One. 2013; 8(10):e77587
  • de Jong HJ, Saldi SR, Klungel OH Vandebriel RJ, Souverein PC, Meyboom RH, Passier JL, Van Loveren H, Cohen Tervaert JW. Statin-associated polymyalgia. An analysis using WHO global individual case safety database: a case/non-case approach. PLoS One. 2012; 7(7):e41289.
  • de Jong HJ, Vandebriel RJ, Saldi SR, Van Dijk L, Van Loveren H, Cohen Tervaert JW, Klungel OH. Angiotensin-converting enzyme inhibitors or angiontensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiol Drug Saf. 2012; 21(8):835-43.
  • Vandebriel RJ, de Jong HJ, Gremmer ER, Klungel OH, Cohen Tervaert JW, Slob W, Van Der Laan JW, Van Loveren H. Statins accelerate the onset of collagen type II-induced arthritis in mice. Arthritis Res Ther. 2012; 14 (2):R90.
  • de Jong HJ, Klungel OH, Van Dijk L, Vandebriel RJ, Leufkens HG, Van der Laan JW, Cohen Tervaert JW, Van Loveren H. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis. 2012; 71(5):648-54.
  • de Jong HJ, Cohen Tervaert JW, Saldi SR, Vandebriel RJ, Souverein PC, Meyboom RH, Van Loveren H, Klungel OH. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum. 2011; 41 (3):373-81.
  • de Jong HJ, De Goede J, Oude Griep LM, Geleijnse JM. Alcohol consumption and blood lipids in elderly coronary patients. Metabolism. 2008; 57(9):1286-92.

Abstracts and Presentations:

  • de Jong HJ, Cohen Tervaert JW, Lalmohamed A, De Vries F, Vandebriel RJ, Van Loveren H, Klungel OH, Van Staa T. Pattern of risks of rheumatoid arthritis among patients using statins: a cohort study with the Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2014; 23(S1):2. [Presented at the 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei, Taiwan, 2014]
  • de Jong HJ, Korevaar JC, Van Dijk L, Voogd E, Van Dijk CE, Van Oijen MG. Suboptimal prescribing of proton pump inhibitors in low-dose aspirin users in general practice. Pharmacoepidemiol Drug Saf. 2013; 22(suppl1):S184. [Presented at the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, QC, 2013]
  • de Jong H, Van dijk L, Voogd E, Korevaar J, Van Oijen M. Redefining gastroprotection in low-dose aspirin users: intentional gastroprotection is very low in general practice. Gut. 2012; 61(suppl3):A92. [Presented at the 20th United European Gastroenterology Week, Amsterdam, The Netherlands, 2012]
  • de Jong H, Saldi S, Klungel O, Vandebriel R, Souverein P, Meyboom R, Van Loveren H, Cohen Tervaert JW. The association between statin use and polymyalgia rheumatic/arteritis temporalis: demonstrated by spontaneous reports and self-described case-reports. Pharmacoepidemiol Drug Saf. 2011; 20(suppl1):S68. [Presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago, IL, 2011]
  • de Jong H, Vandebriel R, Saldi S, Van Dijk L, Van Loveren H, Cohen Tervaert JW, Klungel O. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiol Drug Saf. 2011; 20(suppl1):S67. [Presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago, IL, 2011]
  • Saldi S, de Jong H, Souverein P, Meyboom R, Vandebriel R, Cohen Tervaert JW, Van Loveren H, Klungel O. Association between the use of statins and systemic lupus erythematosus. Pharmacoepidemiol Drug Saf. 2011; 19(suppl1):S148. [Presented at the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Brighton, United Kingdom, 2010 and at the 34th Working group Epidemiological Research Netherlands, Nijmegen, The Netherlands, 2010]
  • de Jong H, Cohen Tervaert JW, Klungel O, Souverein P, Vandebriel R, Damoiseaux J, Van Loveren H, Verschuren M. Statin use and the prevalence of autoantibodies in the Doetinchem cohort. Pharmacoepidemiol Drug Saf. 2011; 19(suppl1):S146. [Presented at the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Brighton, United Kingdom, 2010 and at the 34th Working group Epidemiological Research Netherlands, Nijmegen, The Netherlands, 2010]
  • de Jong H, Klungel O, Van Dijk L, Vandebriel R, Leufkens H, Cohen Tervaert JW, Van Loveren H. Use of statins and the risk of rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2009; 18(suppl1):S126. [Presented at the 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Providence, RI, 2009 and the 33th Working group Epidemiological Research Netherlands, Amsterdam, The Netherlands, 2009]
  • de Jong H, De Goede J, Oude Griep L, Geleijnse M. Alcohol consumption and blood lipids in elderly coronary patients (not published in an international journal). [Presented at the 30th Working group Epidemiological Research Netherlands, Wageningen, The Netherlands, 2005]

a place of mind, The University of British Columbia

Pharmacoepidemiology in MS (PiMS)
2211 Wesbrook Mall,
Vancouver, BC, V6T 2B5, Canada
Email:

Emergency Procedures | Accessibility | Contact UBC  | © Copyright The University of British Columbia